Familial Adenomatous Polyposis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Familial Adenomatous Polyposis – Drugs In Development, 2024 report and make more profitable business decisions.
Familial adenomatous polyposis (FAP) or classic FAP is a genetic condition that causes extra tissue (polyps) to form in large intestine and rectum. It is caused by germline mutations in the APC gene. Symptoms include blood or mucus in the stools, diarrhea or constipation, weight loss due to unknown reason, and abdominal pain. Treatment includes surgery and medications such as non-steroidal anti-inflammatory drugs (NSAIDs).
The Familial Adenomatous Polyposis drugs in development market research report provide comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Familial Adenomatous Polyposis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 18 molecules, with 17 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Familial Adenomatous Polyposis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Familial Adenomatous Polyposis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Familial Adenomatous Polyposis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Amsterdam UMClocation VUmc
Cancer Prevention Pharmaceuticals Inc
Cellix Bio Pvt Ltd
Eloxx Pharmaceuticals Inc
Emtora Biosciences
FunPep Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
KD Pharma Group SA
Panbela Therapeutics Inc
Particella Inc
Recursion Pharmaceuticals Inc
SanaRx Biotherapeutics Inc
Stemsynergy Therapeutics Inc
TherapyX Inc
Thetis Pharmaceuticals LLC
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Familial Adenomatous Polyposis reports